Non-small cell lung cancer recurrent
Information
- Disease name
- Non-small cell lung cancer recurrent
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02423343 | Completed | Phase 1/Phase 2 | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | January 1, 2015 | July 8, 2020 |
| NCT01523340 | Completed | A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response | September 2011 | November 2017 | |
| NCT06463665 | Not yet recruiting | Phase 2 | Efficacy & Safety of Olvimulogene Nanivacirepvec and Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared With Docetaxel in NSCL Cancer (VIRO-25) | July 2024 | July 2029 |
| NCT01774578 | Terminated | Phase 2/Phase 3 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | February 2013 | June 18, 2016 |
| NCT01471964 | Terminated | Phase 1/Phase 2 | Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer | October 20, 2011 | April 10, 2018 |
| NCT02460367 | Terminated | Phase 1 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | January 2016 | January 13, 2021 |
| NCT03445000 | Terminated | Phase 2 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer | November 6, 2018 | March 31, 2021 |